Clinical Trials Logo

Arrhythmias, Cardiac clinical trials

View clinical trials related to Arrhythmias, Cardiac.

Filter by:
  • Active, not recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06031519 Active, not recruiting - Arrhythmia Clinical Trials

Impact of Liwen Procedure in Obstructive Hypertrophic Cardiomyopathy on Arrhythmias

Start date: August 22, 2023
Phase:
Study type: Observational

The goal of this observational study is to learn about the occurrence of various arrhythmias ( tachyarrhythmia and bradyarrhythmia ) during or after Percutaneous Intramyocardial Septal Radiofrequency Ablation. The main questions it aims to answer are: - To investigate the occurrence of various arrhythmias ( tachyarrhythmia and bradyarrhythmia ) during procedure and its relationship with clinical characteristics and procedural parameters - To analyze the changes of 12-lead electrocardiogram and 24-hour dynamic electrocardiogram before and after Percutaneous Intramyocardial Septal Radiofrequency Ablation and their relationships with clinical characteristics and procedural parameters

NCT ID: NCT05872945 Active, not recruiting - Clinical trials for Arrhythmias, Cardiac

Model-based Systems for Professional Football Teams, Aimed at Optimizing Health and Performance

AIPROFB
Start date: July 1, 2019
Phase:
Study type: Observational

LIST OF PLANNED ORIGINAL PUBLICATIONS 1. T wave inversion detection with machine learning to prevent sudden death in professional football players. 2. Machine learning applied to biological parameters for control and advisory in professional football players (Machine learning applied to biological parameters for control and advisory in professional football players.) 3. Machine learning applied to sport geolocation systems for injury prevention in professional football players.

NCT ID: NCT05837364 Active, not recruiting - Clinical trials for Cardiovascular Diseases

Predicting Risk of Atrial Fibrillation and Association With Other Diseases

FIND-AF
Start date: November 2, 2020
Phase:
Study type: Observational

Atrial fibrillation (AF) is a major public health issue: it is increasingly common, incurs substantial healthcare expenditure, and is associated with a range of adverse outcomes. There is rationale for the early diagnosis of AF, before the first complication occurs. Previous AF screening research is limited by low yields of new cases and strokes prevented in the screened populations. For AF screening to be clinically and cost-effective, the efficiency of identification of newly diagnosed AF needs to be improved and the intervention offered may have to extend beyond oral anticoagulation for stroke prophylaxis. Previous prediction models for incident AF have been limited by their data sources and methodologies. An accurate model that utilises existing routinely-collected data is needed to inform clinicians of patient-level risk of AF, inform national screening policy and highlight opportunities to improve patient outcomes from AF screening beyond that of only stroke prevention. The investigators will use routinely-collected hospital-linked primary care data to develop and validate a model for prediction of incident AF within a short prediction horizon, incorporating both a machine learning and traditional regression method. They will also investigate how atrial fibrillation risk is associated with other diseases and death. Using only clinical factors readily accessible in the community, the investigators will provide a method for the identification of individuals in the community who are at risk of AF, thus accelerating research assessing whether atrial fibrillation screening is clinically effective when targeted to high-risk individuals.

NCT ID: NCT05481359 Active, not recruiting - Clinical trials for Cardiovascular Diseases

AF-FLOW Registry: This Study is to Evaluate Ablamap Software in Patients Undergoing Ablation for Atrial Fibrillation.

Start date: September 12, 2022
Phase:
Study type: Observational [Patient Registry]

This post-market global registry will evaluate the ability of the Ablamap® Software to identify atrial fibrillation sources and guide ablation therapy in patients with atrial fibrillation.

NCT ID: NCT05458648 Active, not recruiting - Clinical trials for Persistent Atrial Fibrillation

A Prospective Single Center Pilot Study Using the ECGenius System to Collect Electrogram Data to Test an Ablation Impact Algorithm

Start date: July 28, 2022
Phase:
Study type: Observational

To acquire, amplify, digitize, and record atrial intracardiac electrophysiology signals during cardiac electrophysiology studies for the treatment of persistent atrial fibrillation and to use the recorded data to test the performance of an signal complexity visualization algorithm.

NCT ID: NCT05453097 Active, not recruiting - Cardiac Arrhythmia Clinical Trials

Prognostic Value of the Selvester QRS Score for Perioperative Myocardial Injury Following Non-cardiac Surgery

Start date: August 11, 2022
Phase:
Study type: Observational

The purpose of this study to determine the prognostic value of the Selvester QRS score for perioperative myocardial injury following elective non-cardiac surgery.

NCT ID: NCT05448716 Active, not recruiting - Clinical trials for Congestive Heart Failure

Left Atrial Strain and Supraventricular Arrhythmia Burden in Cardiac Light Chain Amyloidosis Following Chemotherapy

Start date: August 10, 2022
Phase:
Study type: Observational

The purpose of this study to assess the longitudinal changes in left atrial strain and supraventricular arrhythmia burden after chemotherapeutic strategies in cardiac light chain amyloidosis.

NCT ID: NCT05252702 Active, not recruiting - Bradycardia Clinical Trials

Aveir DR i2i Study

Start date: February 2, 2022
Phase: N/A
Study type: Interventional

Prospective, non-randomized, multi-center, international study designed to evaluate the safety and effectiveness of the Aveirâ„¢ Dual-Chamber (DR) Leadless Pacemaker system.

NCT ID: NCT05213104 Active, not recruiting - Clinical trials for Patent Foramen Ovale

Assessment of Flecainide to Lower the Patent Foramen Ovale Closure Risk of Atrial Arrhythmia or Tachycardia

AFLOAT
Start date: March 23, 2022
Phase: Phase 3
Study type: Interventional

About 30% of ischemic strokes are cryptogenic. Patent Foramen Ovale (PFO) is present in about 25% of the general population. In cryptogenic strokes, PFO has been shown to be overrepresented and recent intervention studies have confirmed that PFO has a causal link with stroke. In patients with recent cryptogenic stroke, these randomized studies have shown at least 50%-reduction of recurrent neurological events after PFO percutaneous closure compared with medical therapy alone. At the The risk of AF reported in these studies in certainly largely underestimated as only symptomatic and recorded episodes of AF have been declared. Patients often report palpitations without a dia gnosis of AF made on the ECG or a Holter. Long term ECG monitoring provides more accurate data on AF incidence. Administration of flecainide has been shown to be effective in preventing Atrial arrhythmia and may be useful in preventing these Atrial arrhythmia(AA) episodes after PFO closure. To the knowledge of the investigators, there is no study assessing the efficacy of any antiarrhythmic drug in the prevention of AFafter PFO closure. AFLOAT will be the first randomized study to possibly validate flecainide to prevent Atrial arrhythmia in these patients.

NCT ID: NCT05102227 Active, not recruiting - Clinical trials for Left Bundle Branch Area Pacing

Cardiac ResynchronizatiOn and arrhythmiaS Sensing Via the LEFT Bundle.

CROSS LEFT
Start date: March 25, 2021
Phase:
Study type: Observational

Evaluation of ventricular arrhythmias sensing via a left bundle branch area pacing lead.